StoxDr. Lal Path Labs vs Krishna Institute of Medical Sciences: share price & financials comparison
NSE: LALPATHLAB vs KIMS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Lal Path Labs vs Krishna Institute of Medical Sciences at a glance
Dr. Lal Path Labs (LALPATHLAB) has a market capitalisation of ₹33,057 Cr, against ₹30,366 Cr for Krishna Institute of Medical Sciences (KIMS). Over the past year Dr. Lal Path Labs has returned +27.5%, compared with -1.7% for Krishna Institute of Medical Sciences. On valuation, Dr. Lal Path Labs trades at a lower P/E of 56.7 versus 143.0. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 5.4%). Dr. Lal Path Labs comes out ahead on size, profitability and technicals. Krishna Institute of Medical Sciences comes out ahead on valuation, growth and momentum. Across the scored metrics below, Dr. Lal Path Labs leads on 9 and Krishna Institute of Medical Sciences on 7. On StoxGud's 10-point checklist, Dr. Lal Path Labs scores 9/10 and Krishna Institute of Medical Sciences scores 4/10.
| Metric | Dr. Lal Path Labs | Krishna Institute of Medical Sciences |
|---|---|---|
| Size | ||
| Market cap | ₹33,057 Cr | ₹30,366 Cr |
| Revenue (latest FY) | ₹2,763 Cr | ₹3,905 Cr |
| Net profit (latest FY) | ₹505 Cr | ₹241 Cr |
| Valuation | ||
| P/E | 56.7 | 143.0 |
| P/B | 12.04 | 7.72 |
| Dividend yield | 0.67% | 0.68% |
| Profitability | ||
| Return on equity | 21.3% | 5.4% |
| Net profit margin | 19.2% | 4.6% |
| Operating margin | 29.5% | 19.3% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +39.9% |
| Net profit growth (YoY) | +27.6% | +11.8% |
| Revenue CAGR (multi-year) | +11.8% | +24.0% |
| Financial health | ||
| Debt to equity | 0.00 | 0.90 |
| Momentum | ||
| 1-month return | +1.3% | +4.2% |
| 1-year return | +27.5% | -1.7% |
| 3-year CAGR | +14.2% | +24.8% |
| 5-year CAGR | +1.5% | +25.3% |
| 10-year CAGR | +12.9% | — |
| Distance from 52W high | -2.9% | -15.0% |
| Technicals | ||
| RSI (14) | 65 | 66 |
| Price vs 200-day avg | +19.3% | -0.7% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Lal Path Labs | Krishna Institute of Medical Sciences |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Lal Path Labs or Krishna Institute of Medical Sciences?
Dr. Lal Path Labs has a market cap of ₹33,057 Cr and Krishna Institute of Medical Sciences has a market cap of ₹30,366 Cr as of 06 Nov 2026.
Which has a lower P/E, Dr. Lal Path Labs or Krishna Institute of Medical Sciences?
Dr. Lal Path Labs has the lower P/E: Dr. Lal Path Labs trades at 56.7 and Krishna Institute of Medical Sciences at 143.0.
Which gave better returns in the last year, Dr. Lal Path Labs or Krishna Institute of Medical Sciences?
Dr. Lal Path Labs did better: Dr. Lal Path Labs returned +27.5% and Krishna Institute of Medical Sciences returned -1.7% over one year.
Is Dr. Lal Path Labs or Krishna Institute of Medical Sciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Lal Path Labs scores 9/10 and Krishna Institute of Medical Sciences scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.